Medicine Press release

JFCR and NEC Confirm Research Results for Developing Individualized Neoantigen Cancer Vaccines Using Whole-Genome Data Nov 10, 2025 17:01 JST The Japan Foundation of Cancer Research (JFCR) and NEC Corporation (NEC; TSE: 6701) have confirmed research results supporting the development of a novel personalized neoantigen cancer vaccine using whole-genome data (*1). More info..

JFCR and NEC Confirm Research Results for Developing Individualized Neoantigen Cancer Vaccines Using Whole-Genome Data Nov 10, 2025 17:01 JST The Japan Foundation of Cancer Research (JFCR) and NEC Corporation (NEC; TSE: 6701) have confirmed research results supporting the development of a novel personalized neoantigen cancer vaccine using whole-genome data (*1). More info..

JFCR and NEC Confirm Research Results for Developing Individualized Neoantigen Cancer Vaccines Using Whole-Genome Data Nov 10, 2025 17:01 JST The Japan Foundation of Cancer Research (JFCR) and NEC Corporation (NEC; TSE: 6701) have confirmed research results supporting the development of a novel personalized neoantigen cancer vaccine using whole-genome data (*1). More info..

Olympus Unveils Corporate Strategy
Nov 07, 2025 14:30 JST

Olympus Corporation (Olympus), a global MedTech leader dedicated to making people's lives healthier, safer, and more fulfilling, today unveiled a comprehensive strategy to transform endoscopy-enabled care through innovation and operational excellence.
More info..

Olympus Unveils Corporate Strategy
Nov 07, 2025 14:30 JST

HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
Oct 31, 2025 08:30 JST

HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM).
More info..

HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
Oct 31, 2025 08:30 JST

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma Oct 30, 2025 13:43 JST More info..

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma Oct 30, 2025 13:43 JST More info..

Releases By Industry